Purple Biotech Ltd (PPBT)
NASDAQ: PPBT · Real-Time Price · USD
3.250
-0.130 (-3.85%)
At close: Jan 31, 2025, 4:00 PM
3.370
+0.120 (3.69%)
After-hours: Jan 31, 2025, 7:56 PM EST
Purple Biotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
20
Market Cap
8.87M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 56.33B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
PPBT News
- 2 months ago - Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares - GlobeNewsWire
- 2 months ago - Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares - GlobeNewsWire
- 2 months ago - Why Is Purple Biotech Stock Trading Higher On Monday? - Benzinga
- 2 months ago - Purple Biotech Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death - GlobeNewsWire
- 3 months ago - Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 4 months ago - Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 4 months ago - Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24 - GlobeNewsWire